1. 1969 Tumour infiltrating lymphocytes as a predictive factor for the response to adjuvant endocrine therapy in early breast cancer. (September 2015) Authors: Blok, E.; Engels, C.; Jongste, E.; Dekker-Ensink, G.; Kroep, J.; Kuppen, P.; Van de Velde, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Gene expression signatures in older patients with breast cancer: a systematic review. (October 2022) Authors: Lemij, A.; Baltussen, J.; de Glas, N.; Kroep, J.; Derks, M.; Liefers, G.J.; Portielje, J. Journal: Journal of geriatric oncology Issue: Volume 13(2022)Supplement 1 Page Start: S6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial. (October 2020) Authors: Nuciforo, P.; Townend, J.; Saura, C.; de Azumbaja, E.; Hilbers, F.; Manukyants, A.; Werutsky, G.; Bliss, J.; Moebus, V.; Colleoni, M.; Aspitia, A.Moreno; Di Cosimo, S.; Van dooren, V.; Kroep, J.; Ferro, A.; Cameron, D.; Gelber, R.; Piccart-Gebhart, M.; Huober, J. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OC-0300 Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer. (August 2021) Authors: Post, C.; Mens, J.W.; Haverkort, M.; Koppe, F.; Jürgenliemk-Schulz, I.; Snyers, A.; Roeloffzen, E.; Schaake, E.; Slot, A.; Stam, T.; Beukema, J.; van den Berg, H.; Lutgens, L.; Nijman, H.; de Kroon, C.; Kroep, J.; Stiggelbout, A.; Creutzberg, C. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S206 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006–05). (February 2017) Authors: Van de Velde, C.J.H.; Blok, E.; Meershoek-Klein Kranenbarg, E.; Putter, H.; Van den Bosch, J.; Maartense, E.; Duijm-de Carpentier, M.; Van Leeuwen-Stok, E.; Liefers, G.J.; Nortier, J.; Rutgers, E.; Kroep, J. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Tumor-stroma ratio is associated with Miller-Payne and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer. (October 2020) Authors: Hagenaars, S.; de Groot, S.; Cohen, D.; Charehbili, A.; Dekker, T.; Kranenbarg, E.Meershoek-Klein; Duijm-de Carpentier, M.; Pijl, H.; Putter, H.; Tollenaar, R.; Kroep, J.; Mesker, W. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S106 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗